Issue 9, 2021

Covalent PROTACs: the best of both worlds?

Abstract

Covalent PROTACs combine the cutting edge research areas of targeted covalent inhibitors (TCIs) and proteolysis targeting chimeras (PROTACs). This nascent field of research has already demonstrated several interesting findings, and holds an immense amount of potential to expand the druggable proteome. In this opinion, we present some of these intriguing early findings and discuss the potential advantages and disadvantages of this approach.

Graphical abstract: Covalent PROTACs: the best of both worlds?

Article information

Article type
Opinion
Submitted
09 Jun 2021
Accepted
28 Jun 2021
First published
15 Jul 2021

RSC Med. Chem., 2021,12, 1452-1458

Covalent PROTACs: the best of both worlds?

N. P. Grimster, RSC Med. Chem., 2021, 12, 1452 DOI: 10.1039/D1MD00191D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements